Video Library

Search the Video Library

Filter by Date

Displaying Results 1 - 15 of 63

Please Note: While this is Still Excellent Background Info, New Treatments and Procedures Have Emerged Since this Original Post

Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.


Please Note: New Treatments Have Emerged Since this Original Post

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.

UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.

Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.

Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses Continuing Immunotherapy Beyond Progression-In Which Patients Is This Appropriate

Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses First Line EGFR-Based Therapy For Advanced Squamous Non-Small Cell Lung Cancer (NSCLC).

¿Existe una terapia de mantenimiento mejor sobre las demás?

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding if there is a best maintenance therapy (¿Existe una terapia de mantenimiento mejor sobre las demás?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer

¿Todos deberían de recibir un trasplante autólogo?

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding whether all patients should receive an autologous transplant (¿Todos deberían de recibir un trasplante autólogo?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in

¿Cuáles son los anticuerpos nuevos para la terapia del mieloma múltiple (MM)?

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding the new antibodies for multiple myeloma (MM) therapy (¿Cuáles son los anticuerpos nuevos para la terapia del mieloma múltiple (MM)?). Stay tuned for more on our continuing video series with our Spanish speaking

¿Hay alguna terapia de inducción preferida?

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding if there a preferred induction therapy (¿¿Hay alguna terapia de inducción preferida?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and

Lung Cancer Video Library 2018

Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library. In this video, Dr. West discusses whether immunotherapy works in patients with driver mutations like EGFR and ALK. We thank the

Lung Cancer Video Library 2018

Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library. In this video, Dr. West discusses chemotherapy and immunotherapy combinations in advanced squamous non-small cell lung cancer. We thank

Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Med. Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at FL International University joined GRACE to discuss immune checkpoint inhibitors and how they can treat cancer.

Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University joined GRACE to discuss second-line therapies for advanced NSCLC.